Thyrotoxic periodic paralysis induced by pegylated interferon alpha plus ribavirin for chronic hepatitis C [2]

Journal of Clinical Gastroenterology

Volumn 42, Issue 1, 2008, Pages 112-113

  Yang, Wei Shun ^a   Chu, Pei Lun ^a   Liu, Chen Hua ^a   Chung, Guei Bin ^a   Wu, Kwan Dun ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIMAZOLE; PEGINTERFERON ALPHA2A; PROPRANOLOL; RIBAVIRIN;

ADULT; CASE REPORT; HEPATITIS C; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LETTER; MALE; NEUROLOGIC EXAMINATION; PERIODIC PARALYSIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANTITHYROID AGENTS; ANTIVIRAL AGENTS; CARBIMAZOLE; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; POLYETHYLENE GLYCOLS; PROPRANOLOL; QUADRIPLEGIA; RIBAVIRIN; THYROID DISEASES; TIME FACTORS; TREATMENT OUTCOME;

EID: 37549052475     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000225650.62190.40     Document Type: Letter

References (6)

1. Bini EJ, Mehandru S. Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study. Arch Intern Med. 2004;164:2371-2376.
2. Doi F, Kakizaki S, Takagi H, et al. Longterm outcome of interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. Liver Int. 2005;25:242-246.
3. Kakizaki S, Takagi H, Murakami M, et al. HLA antigens in patients with interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. J Hepatol. 1999;30:794-800.
4. Carella C, Mazziotti G, Amato G, et al. Clinical review 169: Interferon-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab. 2004;89:3656-3661.
5. Lin SH. Thyrotoxic periodic paralysis. Mayo Clin Proc. 2005;80:99-105.
6. Kung AW. Thyrotoxic periodic paralysis: a diagnostic challenge. J Clin Endocrinol Metab. 2006.